Inscripta

About:

Inscripta is a life science technology company that develops digital genome engineering solutions.

Website: https://www.inscripta.com

Twitter/X: inscriptainc

Top Investors: Fidelity, Oak HC/FT, Foresite Capital, Venrock, Paladin Capital Group

Description:

Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.

Total Funding Amount:

$464M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Pleasanton, California, United States

Founded Date:

2015-01-01

Contact Email:

press(AT)inscripta.com

Hub Tags:

Emerging Unicorn

Founders:

Andrew Garst, Ryan T. Gill, Tanya Warnecke

Number of Employees:

51-100

Last Funding Date:

2023-01-18

IPO Status:

Private

© 2025 bioDAO.ai